Christopher R. Richied—Chief Financial Officer

Before joining the Company, Mr. Richied worked in investment banking and biotech venture capital, and was most recently the CFO of AmpliMed Corporation, a clinical-stage cancer pharmaceutical company. Mr. Richied was founding CEO of EnzyMed, a biotech company acquired by Albany Molecular. Previously, he worked in the finance department of the Sanford-Burnham Institute for Medical Research in La Jolla, CA.

Mr. Richied earned his MBA from Harvard Business School, an M.S. in Management Information Systems from the University of Arizona, and a B.S. in Chemical Engineering from Ohio State University.